临床肿瘤学杂志

• 综述与讲座 • 上一篇    下一篇

非小细胞肺癌脑转移药物治疗的研究进展

蔡忠福,欧阳学农,余宗阳   

  1. 福建医科大学福总临床医学院 南京军区福州总医院肿瘤科
  • 收稿日期:2013-09-10 修回日期:2013-11-21 出版日期:2014-04-30 发布日期:2014-04-30
  • 通讯作者: 欧阳学农

Progress of drugs in nonsmall cell lung cancer with brain metastasis

CAI Zhongfu,OUYANG Xuenong,YU Zongyang.   

  1. Department of Oncology, Fuzhou General Hospital of Nanjing Command, Clinical Institute of Fuzhou General Hospital, Fujian Medical University
  • Received:2013-09-10 Revised:2013-11-21 Online:2014-04-30 Published:2014-04-30
  • Contact: OUYANG Xuenong

摘要: 非小细胞肺癌(NSCLC)是最常见的恶性肿瘤之一,也是导致癌症死亡的主要原因,其疗效欠佳、预后差,尤其是伴有脑转移患者。NSCLC伴脑转移患者生活质量差,预后不良,自然中位生存期仅为1~2个月,全脑放射治疗虽然在一定程度上改善了患者的生活质量,延长了患者的生存期,但疗效仍不理想。近年来围绕培美曲塞、替莫唑胺以及表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)开展了一些研究,并取得了一定的成果。本文就针对培美曲塞、替莫唑胺及EGFR-TKIs等抗肿瘤药物在NSCLC伴脑转移中的研究进展进行综述。

Abstract: Non-small cell lung cancer(NSCLC)is one of the most common malignant tumor and a major cause of death from cancer. NSCLC patients often poorly responds to chemotherapy and has a relatively poor prognosis,especially in those patients with brain metastases. NSCLC patients with brain metastases have poor prognosis and worse quality of life; the natural median survival time is only 1-2 months. To some extent,whole brain radiation therapy improves quality of life and prolongs the survival time in NSCLC patients with brain metastases; but the curative effects are still unsatisfactory.In recent years,some research around pemetrexed,temozolomide and epidermal growth factor receptortyrosine kinase inhibitors(EGFR-TKIs)are conducted and achieves certain results. In this paper,we review the progress of drugs in NSCLC with brain metastasis.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!